Chemotherapy-elicited upregulation of NKG2D and DNAM-1 ligands as a therapeutic target in multiple myeloma

Alessandra Soriani, Cinzia Fionda, Biancamaria Ricci, Maria Luisa Iannitto, Marco Cippitelli, Angela Santoni

Research output: Contribution to journalArticlepeer-review

Abstract

Malignant cells constitutively express Natural killer group 2, member D (NKG2D) or DNAX Accessory Molecule-1 (DNAM-1) ligands, yet they are often unable to trigger a robust cytotoxic cell response. It may be therapeutically useful to implement strategies aimed at increasing the density of NKG2D and DNAM-1 ligands on the surface of cancer cells, endowing them with the capacity to activate potent antitumor natural killer-cell responses.

Original languageEnglish
Article numbere26663
JournalOncoImmunology
Volume2
Issue number12
DOIs
Publication statusPublished - 2013

Keywords

  • DNAM-1
  • Multiple myeloma
  • NK cells
  • NKG2D
  • Tumor immunology

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Fingerprint Dive into the research topics of 'Chemotherapy-elicited upregulation of NKG2D and DNAM-1 ligands as a therapeutic target in multiple myeloma'. Together they form a unique fingerprint.

Cite this